ELTX
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Elicio Therapeutics announced activation of an investigator-initiated Phase 1 study of neoadjuvant ELI-002 7P in pancreatic ductal adenocarcinomaAug 10, 2026
- Elicio Therapeutics reported multiple complete responses following ELI-002 7P treatment and checkpoint inhibitor therapy in metastatic KRAS-mutated pancreatic cancerJun 17, 2026
- Elicio Therapeutics reported Phase 2 AMPLIFY-7P results and outlined a refined Phase 3 strategy for ELI-002 7PJun 15, 2026
- Elicio Therapeutics announces investigator-initiated Phase 1 trial to be conducted by Memorial Sloan Kettering Cancer Center funded by Lustgarten Foundation for neoadjuvant ELI-002 7P in pancreatic ductal adenocarcinomaSep 29, 2025
- Elicio Therapeutics reports ELI-002 7P achieved robust mKRAS-specific T cell responses in 99% of evaluable patients in ongoing Phase 2 AMPLIFY-7P trialSep 17, 2025